---
title: "Ultragenyx Phase 3 failure: GTX-102 shows no benefit for Angelman syndrome"
id: "stat-news-0-stat-ultragenyx-drug-to-treat-angelman-syndrome-a-rare-disease-fails-late-stage"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-0-stat-ultragenyx-drug-to-treat-angelman-syndrome-a-rare-disease-fails-late-stage"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "STAT News"
source_url: "https://www.statnews.com/2026/09/02/ultragenyx-drug-angelman-syndrome-clinical-trial/?utm_campaign=rss"
published_at: "2026-09-02T20:37:24.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Ultragenyx Phase 3 failure: GTX-102 shows no benefit for Angelman syndrome
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-0-stat-ultragenyx-drug-to-treat-angelman-syndrome-a-rare-disease-fails-late-stage
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/2026/09/02/ultragenyx-drug-angelman-syndrome-clinical-trial/?utm_campaign=rss)
- **Published At:** 2026-09-02T20:37:24.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Ultragenyx announced that its experimental therapy **GTX-102** met no benefit over a sham treatment in a large **Phase 3** trial for **Angelman syndrome**, according to STAT News. - Angelman syndrome is a rare neurodevelopmental disorder that causes severe intellectual disability and developmental delay; GTX-102 had produced promising and “powerful” signals in earlier, smaller studies that raised hope among families and researchers. - The negative Phase 3 outcome represents a major clinical setback for efforts to treat cognitive and communication impairments in patients with intellectual disabilities and for supporters who had looked to GTX-102 as a potential first-in-class therapy. - The trial failure is also a significant financial and strategic blow to Ultragenyx. The company has other approved treatments, but mostly for ultra-rare conditions; investors had anticipated GTX-102 could help drive broader profitability. - The STAT article was published as a STAT+ exclusive; the publicly available report provides summary conclusions but does not include detailed trial data, such as primary and secondary endpoints, statistical results, trial size, safety and adverse event profiles, or next steps. Those specifics were not reported in the source. - The announcement underscores ongoing challenges in translating early clinical promise in rare neurogenetic disorders into reproducible Phase 3 benefit, and it leaves open questions about what the company and the field will do next to develop therapies for Angelman syndrome.
## Clinical Analysis & Structured Key Points
[Skip to Main Content](https://www.statnews.com/2026/09/02/ultragenyx-drug-angelman-syndrome-clinical-trial/?utm_campaign=rss#wrapper) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo-white.svg) ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * Email this article * [Share this article](https://www.statnews.com/2026/09/02/ultragenyx-drug-angelman-syndrome-clinical-trial/?utm_campaign=rss) [research](https://www.statnews.com/topic/research/) [patients](https://www.statnews.com/topic/patients/) [Mental Health](https://www.statnews.com/topic/mental-health/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) My Account * [Settings Complete your personal information for a more tailored experience ](https://www.statnews.com/my-account/) * [Billing](https://www.statnews.com/my-account/billing/) * [Log In](https://www.statnews.com/login/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) Reporting from the frontiers of health and medicine ](https://www.statnews.com/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Public Health](https://www.statnews.com/category/health/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Policy](https://www.statnews.com/category/politics/) * [Science](https://www.statnews.com/category/in-the-lab/) * [First Opinion](https://www.statnews.com/category/first-opinion/) * [STAT+](https://www.statnews.com/topic/stat-plus/) * [STAT Events](https://www.statnews.com/events/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) Search * [Log In](https://www.statnews.com/login/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [My Account](https://www.statnews.com/my-account/) [Home](https://www.statnews.com/) News * [Latest](https://www.statnews.com/latest/) * [Series & Investigations](https://www.statnews.com/stat-series-and-investigations-award-winning-journalism/) * Business * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Health Insurance](https://www.statnews.com/category/insurance/) * [Hospitals](https://www.statnews.com/category/hospitals/) * [Medical Devices](https://www.statnews.com/topic/medical-devices/) * Washington * [Policy](https://www.statnews.com/category/politics/) * [FDA](https://www.statnews.com/topic/fda/) * [NIH](https://www.statnews.com/topic/nih/) * Science * [CRISPR](https://www.statnews.com/topic/crispr/) * [Gene Therapy](https://www.statnews.com/topic/gene-therapy/) * [Neuroscience](https://www.statnews.com/topic/neuroscience/) * Public Health * [Addiction](https://www.statnews.com/topic/addiction/) * [Covid-19](https://www.statnews.com/topic/coronavirus/) * [Abortion](https://www.statnews.com/topic/abortion/) * [Health Disparities](https://www.statnews.com/topic/health-disparities/) * [Infectious Disease](https://www.statnews.com/topic/infectious-disease/) * [Mental Health](https://www.statnews.com/topic/mental-health/) * Disease * [Cancer](https://www.statnews.com/topic/cancer/) * [Cardiovascular Disease](https://www.statnews.com/topic/cardiovascular-disease/) * [Chronic Disease](https://www.statnews.com/topic/chronic-disease/) * [Diabetes](https://www.statnews.com/topic/diabetes/) * [Alzheimer's](https://www.statnews.com/topic/alzheimers/) * [Obesity](https://www.statnews.com/topic/obesity/) * Features * [Health Care Costs](https://www.statnews.com/health-insurance-costs-out-of-pocket-out-of-reach-series/) * [The Deadliest Drug](https://www.statnews.com/alcohol-epidemic-hiding-plain-sight-deadliest-drug-series/) * [Science, Shattered](https://www.statnews.com/american-science-shattered/) [Newsletters](https://www.statnews.com/signup/) [Opinion](https://www.statnews.com/category/first-opinion/) Columns * [Adam Feuerstein](https://www.statnews.com/category/adams-take/) * [Matthew Herper](https://www.statnews.com/category/matts-take/) * [Ed Silverman](https://www.statnews.com/category/pharmalot-view/) [Reports](https://reports.statnews.com/) [E-books](https://www.statnews.com/ebooks/) [Podcasts](https://www.statnews.com/podcasts/) [Tools & Trackers](https://www.statnews.com/trackers/) * [CRISPR Tracker](https://www.statnews.com/feature/crispr/tracker/) * [Breakthrough Device Tracker](https://www.statnews.com/feature/stat-plus/breakthrough-device-designation-fda-tracker/) * [Generative AI Tracker](https://www.statnews.com/feature/stat-plus/generative-ai-health-hospitals-tracker/) * [Obesity Drug Tracker](https://www.statnews.com/2023/09/12/new-weight-loss-drug-tracker-novo-nordisk-eli-lilly/) [Events](https://www.statnews.com/events/) * [Upcoming Events](https://www.statnews.com/events#upcoming-events) * [Summits](https://www.statnews.com/stat-summits/) [Community](https://www.statnews.com/community/) * [STAT Wunderkinds 2026](https://www.statnews.com/wunderkinds-nominate/) [Video](https://youtube.com/@Statnews) [Advertise](https://www.statnews.com/advertise/) * [STAT Brand Studio](https://sbs.statnews.com/) What's the word? Test your knowledge with our new weekday mini crossword [ Start solving ](https://www.statnews.com/stat-mini-crossword/) [STAT Plus](https://www.statnews.com/stat-plus/)[Biotech](https://www.statnews.com/category/biotech/) # Ultragenyx drug to treat Angelman syndrome, a rare disease, fails late-stage trial ## Therapy had shown potential in earlier trials, raising hopes for families * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * Email this article * [Share this article](https://www.statnews.com/2026/09/02/ultragenyx-drug-angelman-syndrome-clinical-trial/?utm_campaign=rss) ![A Exterior of the new Ultragenyx biomanufacturing plant. -- biotech coverage from STAT](https://www.statnews.com/wp-content/uploads/2024/05/s3___bgmp-arc_arc-feeds_generic-photos_to-arc_Wiggs-_Bedford_2-645x645.jpg) Jonathan Wiggs /Globe Staff ![](https://www.statnews.com/wp-content/uploads/2022/05/jason-mast-avatar-round-80x80.png) By [Jason Mast](https://www.statnews.com/staff/jason-mast/) Sept. 2, 2026 General Assignment Reporter ![](https://www.statnews.com/wp-content/uploads/2022/05/jason-mast-avatar-round-80x80.png) [Jason Mast](https://www.statnews.com/staff/jason-mast/) 1. [](https://x.com/JasonMMast "X") jason.mast@statnews.com Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. The biotech company Ultragenyx said Wednesday that its experimental therapy for Angelman syndrome, a rare disease that causes severe intellectual disabilities and developmental delays, showed no benefit compared to a sham treatment in a large Phase 3 trial. The drug, GTX-102, had shown powerful results in early trials, raising the hopes of families affected by the devastating condition. Many advocates for patients with other neurological conditions also hoped it could be the first of many medicines that improve cognition, communication, and other aspects of the lives of patients with intellectual disabilities. Advertisement The news is a significant blow for Ultragenyx’s business as well. Although the company has multiple approved medicines, they are for mostly ultra-rare diseases, and investors had been banking on the Angelman drug as the company’s path to profitability. STAT+ Exclusive Story Already have an account? [Log in](https://www.statnews.com/login/) ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-breaker-bg.png) [ ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo-white.svg) ](https://www.statnews.com/stat-plus/) ## This article is exclusive to STAT+ subscribers ### Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? [Log in](https://www.statnews.com/login/) Individual plans Group plans Monthly $39 Totals $468 per year [$39/month](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) Totals $468 per year Starter $30 for 3 months, then $399/year [$30 for 3 months](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) Then $399/year Annual $399 Save 15% [$399/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) Save 15% 11+ Users Custom Savings start at 25%! [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) Savings start at 25%! 2-10 Users $300 Annually per user [$300/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) $300 Annually per user [View All Plans](https://www.statnews.com/stat-plus/) [![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo.svg)](https://www.statnews.com/stat-plus/) To read the rest of this story subscribe to STAT+. [Subscribe](https://www.statnews.com/stat-plus/) [Log In](https://www.statnews.com/login/) [biotechnology](https://www.statnews.com/topic/biotechnology/), [drug development](https://www.statnews.com/topic/drug-development/), [Pharmaceuticals](https://www.statnews.com/topic/pharmaceuticals/), [rare diseases](https://www.statnews.com/topic/rare-diseases/), [STAT+](https://www.statnews.com/topic/stat-plus/) [Submit a correction request](https://www.statnews.com/contact/?how_can_we_help_=Editorial%20Correction%20Request)[Reprints](https://www.parsintl.com/publications/stat/) 1. ![](https://www.statnews.com/wp-content/uploads/2022/05/jason-mast-avatar-round-80x80.png) [Jason Mast](https://www.statnews.com/staff/jason-mast/) 1. [](https://x.com/JasonMMast "X") 2. General Assignment Reporter 1. [](https://x.com/JasonMMast "X") 2. Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. ![](https://www.statnews.com/wp-content/themes/stat/images/article-new/envelope-open.svg) ![](https://www.statnews.com/wp-content/uploads/2023/06/The-Readout-Logo-Black-640x99.png) ### Newsletter Your morning rundown of the science, politics, and money driving biotech today Please enter a valid email address. Sign Up Your data will be processed in accordance with our [Privacy Policy](https://www.statnews.com/privacy/) and [Terms of Service](https://www.statnews.com/terms-conditions/). You may opt out of receiving STAT communications at any time. Advertisement Most Popular 1. ![](https://www.statnews.com/wp-content/uploads/2026/08/AdobeStock_578977705-80x80.jpeg) [Doctors groups release vaccination guidelines ahead of respiratory illness season](https://www.statnews.com/2026/09/02/vaccine-integrity-project-fall-winter-guidelines-rsv-covid-flu-shots/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/06/conference-center-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ADA review of members’ expulsion denies group censored opinions, called in police](https://www.statnews.com/2026/09/01/ada-members-review-june-expulsion-denies-censoring-opinions-calling-new-orleans-police/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/08/GettyImages-2292880922-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [How Trump’s latest pharma deals may undermine efforts to rein in drug costs](https://www.statnews.com/2026/09/02/trump-most-favored-nation-drug-pricing-industry-analysts-skeptical/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/06/IMG_9697-80x80.jpeg) [Diabetes association CEO: What an independent review says happened at the ADA’s controversial June conference](https://www.statnews.com/2026/09/01/american-diabetes-association-june-conference-independent-review/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/08/AP26231616995533-80x80.jpg) [I’m a reproductive psychiatrist. The Lindsay Clancy trial will cause terrible damage to my field](https://www.statnews.com/2026/09/01/lindsay-clancy-trial-verdict-postpartum-psychosis-psychiatry/) #### [ Reports ](https://reports.statnews.com/) [ ![](https://www.statnews.com/wp-content/uploads/2026/08/2026_CancerReport_ReportCover-328x424.jpg) Explore Cancer’s transformational moments: KRAS, CAR-T, immunotherapy, and more ](https://reports.statnews.com/products/cancer-transformational-moments-advances-in-kras-car-t-immunotherapy) Advertisement #### [Events](https://www.statnews.com/events/) [ ![](https://www.statnews.com/wp-content/uploads/2026/07/924_Samsung_VirtualEvent_Wordpress_FeaturedImage-80x80.jpg) Biosimilars: Have We Reached an Inflection Point? Virtual Sep 24 ](https://www.statnews.com/event/biosimilars-what-is-next-virtual-event-sept-2026/) [ ![](https://www.statnews.com/wp-content/uploads/2026/01/Flagship2026_Wordpress_CalendarImageRegGoLive-1-80x80.jpg) 2026 STAT Summit Boston, MA Oct 14 ](https://www.statnews.com/event/2026-stat-summit/) [ ![](https://www.statnews.com/wp-content/uploads/2026/07/2026_DD_OfficeHours_VirtualEvent_Wordpress_CalendarImage-80x80.jpg) Office Hours with Isabella Cueto and Lev Facher Virtual Jul 29 ](https://www.statnews.com/event/deadliest-drug-series-office-hours-ama-july-2026/) Most Read in [STAT+](https://www.statnews.com/stat-plus/) 1. ![](https://www.statnews.com/wp-content/uploads/2026/08/AdobeStock_1240429246-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [NIH proposal to cap research grants draws mixed reception, agency says](https://www.statnews.com/2026/09/01/nih-grant-cap-proposal-researcher-feedback/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/08/marc-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Former Stanford president releases emails to rebut fraud and cover-up allegations in new book](https://www.statnews.com/2026/08/27/marc-tessier-lavigne-responds-theo-baker-book-misconduct-stanford-genentech/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/08/Revmed_campus2-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [FDA approves new pancreatic cancer drug expected to usher in new era of treatment](https://www.statnews.com/2026/08/26/pancreatic-cancer-drug-rasonque-approved/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/08/AdobeStock_182456094-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [After a rough stretch, mRNA gets a boost — at least for now](https://www.statnews.com/2026/08/31/mrna-cancer-vaccine-intersects-politics-medicine/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/08/AdobeStock_998225050-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [The mystery of Moderna’s magic algorithm](https://www.statnews.com/2026/08/27/moderna-merck-cancer-vaccine-secret-ingredient-an-algorithm/) #### Recommended ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) The Readout The Readout September 2, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: ARPA-H funds biotechs working on custom RNA therapies ](https://www.statnews.com/2026/09/02/biotech-news-arp-h-funds-biotechs-working-on-custom-rna-therapies/) By [Elaine Chen](https://www.statnews.com/staff/elaine-chen/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Politics Politics September 1, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: 5 burning questions on Trump’s latest deals with drugmakers ](https://www.statnews.com/2026/09/01/trump-pharma-deals-analysis-latest-round-most-favored-nation-drug-pricing/) By [Daniel Payne](https://www.statnews.com/staff/daniel-payne/), [Elaine Chen](https://www.statnews.com/staff/elaine-chen/), and [John Wilkerson](https://www.statnews.com/staff/john-wilkerson/) Advertisement ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) The Readout The Readout September 1, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Novartis gets multiple sclerosis win with BTK inhibitor ](https://www.statnews.com/2026/09/01/biotech-news-novartis-gets-multiple-sclerosis-win-with-btk-inhibitor/) By [Elaine Chen](https://www.statnews.com/staff/elaine-chen/) and [Helen Branswell](https://www.statnews.com/staff/helen-branswell/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) D.C. Diagnosis D.C. Diagnosis September 1, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Will House delay Trump plan to politicize NIH grants? ](https://www.statnews.com/2026/09/01/house-spending-bill-vote-grant-rule-trump-mfn-deals-dc-diagnois/) By [John Wilkerson](https://www.statnews.com/staff/john-wilkerson/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Pharma Pharma August 31, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Trump strikes nine more deals with drugmakers to lower prices ](https://www.statnews.com/2026/08/31/trump-most-favored-nation-drug-pricing-new-round-price-cuts-announced/) By [Daniel Payne](https://www.statnews.com/staff/daniel-payne/) and [Elaine Chen](https://www.statnews.com/staff/elaine-chen/) #### Subscriber Picks 1. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs ](https://www.statnews.com/2026/08/28/astrazeneca-ionis-wainua-eplontersen-attr-cm-study-failure-bridgebio-alnylam/) By [Andrew Joseph](https://www.statnews.com/staff/andrew-joseph/) 2. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Former Stanford president releases emails to rebut fraud and cover-up allegations in new book ](https://www.statnews.com/2026/08/27/marc-tessier-lavigne-responds-theo-baker-book-misconduct-stanford-genentech/) By [Jonathan Wosen](https://www.statnews.com/staff/jonathan-wosen/) 3. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: When it comes to women’s health, money talks ](https://www.statnews.com/2026/08/26/womens-health-reverse-pitch-profit-driven-approach-endometriosis-osteoporosis/) By [Elizabeth Cooney](https://www.statnews.com/staff/elizabeth-cooney/) 4. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT P
## Related Clinical Research

- [Novartis scores multiple sclerosis outcome with BTK inhibitor](https://medichelpline.com/clinical-feed/stat-news-1-stat-novartis-gets-multiple-sclerosis-win-with-btk-inhibitor.md)
- [Reduced added sugar in the first 1,000 days tied to lower Alzheimer’s and dementia risk](https://medichelpline.com/clinical-feed/medical-news-today-0-cutting-added-sugar-before-age-2-linked-to-lower-dementia-depression-risk-in.md)
- [Time-restricted eating tied to improved cognitive performance in small pilot study](https://medichelpline.com/clinical-feed/medical-news-today-0-time-restricted-eating-linked-to-better-cognitive-function-in-pilot-study.md)
- [Fauci on pandemic memory: selective amnesia and its effect on views of masking and lockdowns](https://medichelpline.com/clinical-feed/stat-news-1-stat-fauci-speaks-and-writes.md)
- [Cardiac-targeted delivery strategies for advanced therapies in heart disease](https://medichelpline.com/clinical-feed/pubmed-42284133.md) (DOI: 10.1093/eurheartj/ehag432)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.